A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay

J. M S Bartlett, Fiona M. Campbell, Merdol Ibrahim, Anthony O'Grady, Elaine Kay, Catherine Faulkes, Nadine Collins, Jane Starczynski, John M. Morgan, Bharat Jasani, Keith Miller

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

We performed a multicenter assessment of a new HER2 dual-color chromogenic in situ hybridization (CISH) test and herein report on concordance of CISH data with fluorescence in situ hybridization (FISH) data and intraobserver and interlaboratory scoring consistency. HER2 results were evaluated using duplicate cores from 30 breast cancers in 5 laboratories using the Ventana HER2 dual-color ISH assay (Ventana Medical Systems, Cambridgeshire, England) and in 1 central laboratory using a standard FISH assay. Overall 93.3% of cases were successfully analyzed by CISH across the 5 participating laboratories. There was excellent concordance (98.0% overall) for diagnosis of HER2 amplification by CISH compared with FISH. Intraobserver variability (7.7%) and intersite variability (9.1%) of absolute HER2/ chromosome enumeration probe 17 ratios were tightly controlled across all participating laboratories. The Ventana HER2 dual-color ISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national and international guidelines for performance of ISH-based diagnostic tests.

Original languageEnglish
Pages (from-to)157-162
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume135
Issue number1
DOIs
Publication statusPublished - Jan 2011
Externally publishedYes

Fingerprint

Fluorescence In Situ Hybridization
Multicenter Studies
In Situ Hybridization
Color
Observer Variation
Routine Diagnostic Tests
England
Chromosomes
Guidelines
Breast Neoplasms

Keywords

  • Amplification
  • Breast neoplasms
  • Chromogenic in situ hybridization
  • CISH
  • Consistency
  • FISH
  • Fluorescence in situ hybridization
  • HER2
  • Intersite
  • Intraobserver
  • NEQAS

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Bartlett, J. M. S., Campbell, F. M., Ibrahim, M., O'Grady, A., Kay, E., Faulkes, C., ... Miller, K. (2011). A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. American Journal of Clinical Pathology, 135(1), 157-162. https://doi.org/10.1309/AJCPVPRKK1ENEDGQ

A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. / Bartlett, J. M S; Campbell, Fiona M.; Ibrahim, Merdol; O'Grady, Anthony; Kay, Elaine; Faulkes, Catherine; Collins, Nadine; Starczynski, Jane; Morgan, John M.; Jasani, Bharat; Miller, Keith.

In: American Journal of Clinical Pathology, Vol. 135, No. 1, 01.2011, p. 157-162.

Research output: Contribution to journalArticle

Bartlett, JMS, Campbell, FM, Ibrahim, M, O'Grady, A, Kay, E, Faulkes, C, Collins, N, Starczynski, J, Morgan, JM, Jasani, B & Miller, K 2011, 'A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay', American Journal of Clinical Pathology, vol. 135, no. 1, pp. 157-162. https://doi.org/10.1309/AJCPVPRKK1ENEDGQ
Bartlett, J. M S ; Campbell, Fiona M. ; Ibrahim, Merdol ; O'Grady, Anthony ; Kay, Elaine ; Faulkes, Catherine ; Collins, Nadine ; Starczynski, Jane ; Morgan, John M. ; Jasani, Bharat ; Miller, Keith. / A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay. In: American Journal of Clinical Pathology. 2011 ; Vol. 135, No. 1. pp. 157-162.
@article{0708a1edb3fd4ad4ae2a258d0209a4b4,
title = "A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay",
abstract = "We performed a multicenter assessment of a new HER2 dual-color chromogenic in situ hybridization (CISH) test and herein report on concordance of CISH data with fluorescence in situ hybridization (FISH) data and intraobserver and interlaboratory scoring consistency. HER2 results were evaluated using duplicate cores from 30 breast cancers in 5 laboratories using the Ventana HER2 dual-color ISH assay (Ventana Medical Systems, Cambridgeshire, England) and in 1 central laboratory using a standard FISH assay. Overall 93.3{\%} of cases were successfully analyzed by CISH across the 5 participating laboratories. There was excellent concordance (98.0{\%} overall) for diagnosis of HER2 amplification by CISH compared with FISH. Intraobserver variability (7.7{\%}) and intersite variability (9.1{\%}) of absolute HER2/ chromosome enumeration probe 17 ratios were tightly controlled across all participating laboratories. The Ventana HER2 dual-color ISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national and international guidelines for performance of ISH-based diagnostic tests.",
keywords = "Amplification, Breast neoplasms, Chromogenic in situ hybridization, CISH, Consistency, FISH, Fluorescence in situ hybridization, HER2, Intersite, Intraobserver, NEQAS",
author = "Bartlett, {J. M S} and Campbell, {Fiona M.} and Merdol Ibrahim and Anthony O'Grady and Elaine Kay and Catherine Faulkes and Nadine Collins and Jane Starczynski and Morgan, {John M.} and Bharat Jasani and Keith Miller",
year = "2011",
month = "1",
doi = "10.1309/AJCPVPRKK1ENEDGQ",
language = "English",
volume = "135",
pages = "157--162",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay

AU - Bartlett, J. M S

AU - Campbell, Fiona M.

AU - Ibrahim, Merdol

AU - O'Grady, Anthony

AU - Kay, Elaine

AU - Faulkes, Catherine

AU - Collins, Nadine

AU - Starczynski, Jane

AU - Morgan, John M.

AU - Jasani, Bharat

AU - Miller, Keith

PY - 2011/1

Y1 - 2011/1

N2 - We performed a multicenter assessment of a new HER2 dual-color chromogenic in situ hybridization (CISH) test and herein report on concordance of CISH data with fluorescence in situ hybridization (FISH) data and intraobserver and interlaboratory scoring consistency. HER2 results were evaluated using duplicate cores from 30 breast cancers in 5 laboratories using the Ventana HER2 dual-color ISH assay (Ventana Medical Systems, Cambridgeshire, England) and in 1 central laboratory using a standard FISH assay. Overall 93.3% of cases were successfully analyzed by CISH across the 5 participating laboratories. There was excellent concordance (98.0% overall) for diagnosis of HER2 amplification by CISH compared with FISH. Intraobserver variability (7.7%) and intersite variability (9.1%) of absolute HER2/ chromosome enumeration probe 17 ratios were tightly controlled across all participating laboratories. The Ventana HER2 dual-color ISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national and international guidelines for performance of ISH-based diagnostic tests.

AB - We performed a multicenter assessment of a new HER2 dual-color chromogenic in situ hybridization (CISH) test and herein report on concordance of CISH data with fluorescence in situ hybridization (FISH) data and intraobserver and interlaboratory scoring consistency. HER2 results were evaluated using duplicate cores from 30 breast cancers in 5 laboratories using the Ventana HER2 dual-color ISH assay (Ventana Medical Systems, Cambridgeshire, England) and in 1 central laboratory using a standard FISH assay. Overall 93.3% of cases were successfully analyzed by CISH across the 5 participating laboratories. There was excellent concordance (98.0% overall) for diagnosis of HER2 amplification by CISH compared with FISH. Intraobserver variability (7.7%) and intersite variability (9.1%) of absolute HER2/ chromosome enumeration probe 17 ratios were tightly controlled across all participating laboratories. The Ventana HER2 dual-color ISH assay is robust and reproducible, shows good concordance with a standard FISH assay, and complies with requirements in national and international guidelines for performance of ISH-based diagnostic tests.

KW - Amplification

KW - Breast neoplasms

KW - Chromogenic in situ hybridization

KW - CISH

KW - Consistency

KW - FISH

KW - Fluorescence in situ hybridization

KW - HER2

KW - Intersite

KW - Intraobserver

KW - NEQAS

UR - http://www.scopus.com/inward/record.url?scp=79251525873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251525873&partnerID=8YFLogxK

U2 - 10.1309/AJCPVPRKK1ENEDGQ

DO - 10.1309/AJCPVPRKK1ENEDGQ

M3 - Article

VL - 135

SP - 157

EP - 162

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -